" class="no-js "lang="en-US"> Eton Acquires of Rare Disease Product Candidate ET-600
Thursday, March 23, 2023

Breaking News

Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Medtronic to Boost AI Innovation with New Platform Introduction Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 | MTA

March 15 2023

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the United States.

“As a rare disease product that builds on our established presence in pediatric endocrinology, ET-600 is a perfect strategic fit for our portfolio,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We have repeatedly heard from physicians about their need for this product to effectively and safely treat their pediatric patients, so we look forward to working to bring this potential new treatment option to the market.”

Eton expects to submit a New Drug Application (NDA) for the product to the U.S. Food and Drug Administration in the second quarter of 2024, which could allow for an approval and launch of the product in early 2025. If approved, ET-600 is expected to be a patent-protected, durable product that can generate significant long-term revenue and profit for the company.

  1. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

    News

     Read more
  2. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

    Diseases

     Read more
  3. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

    Drug Development

     Read more
  4. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

    News

     Read more
  5. Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President

    Appointments

     Read more
More On